Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Emergency Drug for Cardiac Arrest

30.09.2002


Vasopressin as an agent for cardio-pulmonary resuscitation



Diseases of the cardiovascular system continue to be the most frequent causes of death in the Western world. For over 100 years, Adrenaline has been the standard drug of choice in the treatment of sudden cardiac arrest. A team of researchers headed by Karl H. Lindner and Volker Wenzel from the University Department of Anaesthesiology and Critical Care Medicine, University of Innsbruck, has, with the support of the Austrian Science Fund (FWF) and after years of successful investigations, proved that Vasopressin is at least as successful as Adrenaline as an emergency drug used in cardio-pulmonary resuscitation.

In fact, in 2000 the findings of the Innsbruck anaesthetists led to a change in the international guidelines concerning cardio-pulmonary resuscitation. Since then, Vasopressin has been recommended as a therapy to adult patients suffering from ventricular flutter. Vasopressin improves blood pressure during cardio-pulmonary resuscitation, thus probably increasing the chances of survival of patients with cardiac arrest. As Dr. Wenzel explained, "We have detected a high dosage of endogenic Vasopressin in patients who survived a cardiac arrest. We concluded from this that the body releases more of this substance in this life-threatening situation. Our research has confirmed the assumption that Vasopressin is also of use when injected by an emergency doctor: the chances of survival within the first 24 hours after a cardiac arrest is thus increased.“


Clinical trial soon to be completed

The possible advantage of Vasopressin over Adrenaline shall now be checked on the basis of data obtained in an international clinical trial which was organised by the Innsbruck scientists and included 1219 patients in 33 emergency medical service units in Austria, Switzerland and Germany.

The results shall shortly be presented to international experts before being published in an internationally renowned magazine.

"If the data arrived at from the study meets our expectations, Vasopressin could be authorised for the treatment of patients with cardiac arrest. At present, although the international guidelines expressly recommend Vasopressin, the drug has not been officially sanctioned for such an application", Dr. Wenzel said, and he continued, "In clinical practice Vasopressin is frequently used, and several patients have benefited from its administration. However, the legal framework is somewhat lagging behind this development."

Nevertheless, among experts the achievements of the Innsbruck anaesthetists have been honoured with prizes on more than one occasion, among them the Hoechst Prize of the University of Innsbruck, the award for emergency and intensive care medicine of the universities of Munich and Munster, and prizes of the American Heart Association and the American Society of Critical Care Medicine.

Alexandra Stolba | alfa

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>